DK3956324T3 - 1,3,4-oxadiazol-derivater som histondeacetylase-inhibitorer - Google Patents

1,3,4-oxadiazol-derivater som histondeacetylase-inhibitorer Download PDF

Info

Publication number
DK3956324T3
DK3956324T3 DK20717897.1T DK20717897T DK3956324T3 DK 3956324 T3 DK3956324 T3 DK 3956324T3 DK 20717897 T DK20717897 T DK 20717897T DK 3956324 T3 DK3956324 T3 DK 3956324T3
Authority
DK
Denmark
Prior art keywords
histone deacetylase
oxadiazole derivatives
deacetylase inhibitors
inhibitors
oxadiazole
Prior art date
Application number
DK20717897.1T
Other languages
English (en)
Inventor
Richard Spurring Roberts
Salazar Yosu Ion Vara
Arévalo Eneko Aldaba
Iglesias Tamara Bello
Buela Laureano Simón
José Manuel Brea
Ángel Carracedo
García María Isabel Loza
Original Assignee
Quimatryx S L
Fund Kertor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quimatryx S L, Fund Kertor filed Critical Quimatryx S L
Application granted granted Critical
Publication of DK3956324T3 publication Critical patent/DK3956324T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK20717897.1T 2019-04-17 2020-04-16 1,3,4-oxadiazol-derivater som histondeacetylase-inhibitorer DK3956324T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382306 2019-04-17
PCT/EP2020/060695 WO2020212479A1 (en) 2019-04-17 2020-04-16 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors

Publications (1)

Publication Number Publication Date
DK3956324T3 true DK3956324T3 (da) 2024-05-13

Family

ID=66240040

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20717897.1T DK3956324T3 (da) 2019-04-17 2020-04-16 1,3,4-oxadiazol-derivater som histondeacetylase-inhibitorer

Country Status (11)

Country Link
US (1) US12202823B2 (da)
EP (1) EP3956324B1 (da)
JP (1) JP7593647B2 (da)
KR (1) KR20220012243A (da)
CN (1) CN114269739B (da)
AU (1) AU2020259100B2 (da)
BR (1) BR112021020682A2 (da)
CA (1) CA3137054A1 (da)
DK (1) DK3956324T3 (da)
ES (1) ES2984772T3 (da)
WO (1) WO2020212479A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
MY207444A (en) 2019-05-31 2025-02-27 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
TWI748492B (zh) * 2019-05-31 2021-12-01 韓商鐘根堂股份有限公司 作為組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑衍生物及含彼之醫藥組合物
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
JP7571276B2 (ja) * 2020-07-14 2024-10-22 チョン クン ダン ファーマシューティカル コーポレイション ヒストン脱アセチル化酵素６阻害剤としての新規な構造の化合物およびこれを含む薬剤学的組成物
KR20230049675A (ko) * 2020-08-07 2023-04-13 이탈파마코 에스.피.에이. 신규한 옥사디아졸-기반 선택적 hdac6 억제제
KR102685058B1 (ko) 2020-09-02 2024-07-15 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물
EP4494640A4 (en) * 2022-03-17 2026-05-06 Univ Sookmyung Womens Ind Acad Coop Found Novel heterocyclic inhibitor for histone deacetylase, and pharmaceutical composition comprising same
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途
CN114634489B (zh) * 2022-04-19 2023-07-04 奎马特里克斯有限公司 结晶形式
CN119451953A (zh) * 2022-07-15 2025-02-14 株式会社 钟根堂 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑三唑化合物和包含其的药物组合物
TW202412772A (zh) * 2022-07-19 2024-04-01 義大利商義大利藥品股份有限公司 作為選擇性組蛋白去乙醯酶６抑制劑之１，３，４－㗁二唑衍生物
CA3262628A1 (en) 2022-08-08 2024-02-15 Italfarmaco S.P.A. HYDRAZIDES DIFLOORO- AND TRIFLUORO-ACETYLE USED AS SELECTIVE HDAC6 INHIBITORS
KR20240035172A (ko) * 2022-09-08 2024-03-15 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305643A1 (en) 2009-10-02 2011-04-06 Ikerchem, S.L. New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers
WO2013066838A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
PL3328843T3 (pl) * 2015-07-27 2023-02-27 Chong Kun Dang Pharmaceutical Corp. Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca
CN108026056B (zh) 2015-07-27 2021-08-03 株式会社钟根堂 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑酰胺衍生物化合物及其药物组合物
RU2695227C9 (ru) * 2015-07-27 2020-03-04 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
JP6491393B2 (ja) * 2015-08-04 2019-03-27 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾール誘導体化合物及びこれを含有する薬剤学的組成物
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
CN107879975B (zh) * 2016-09-30 2022-07-26 中国科学院上海药物研究所 组蛋白去乙酰化酶抑制剂及其应用
EP3318256A1 (en) 2016-11-08 2018-05-09 Quimatryx, S.L Compounds for the treatment of autoimmune diseases
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN111032651A (zh) * 2017-07-31 2020-04-17 武田药品工业株式会社 杂环化合物

Also Published As

Publication number Publication date
AU2020259100B2 (en) 2024-12-12
JP7593647B2 (ja) 2024-12-03
WO2020212479A1 (en) 2020-10-22
CN114269739B (zh) 2025-04-22
US20220213084A1 (en) 2022-07-07
CN114269739A (zh) 2022-04-01
JP2022529695A (ja) 2022-06-23
BR112021020682A2 (pt) 2021-12-07
ES2984772T3 (es) 2024-10-31
AU2020259100A1 (en) 2021-11-11
EP3956324B1 (en) 2024-02-21
CA3137054A1 (en) 2020-10-22
EP3956324A1 (en) 2022-02-23
KR20220012243A (ko) 2022-02-03
US12202823B2 (en) 2025-01-21

Similar Documents

Publication Publication Date Title
DK3956324T3 (da) 1,3,4-oxadiazol-derivater som histondeacetylase-inhibitorer
IL274973A (en) History of 4,2,1-oxadiazole as histone deacetylase inhibitors
DK3328844T3 (da) 1,3,4-oxadiazolsulfamidderivater som histondeacetylase-6-inhibitor og farmaceutisk sammensætning omfattende samme
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
DK3331864T3 (da) 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse
FI3328843T3 (fi) 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus
DK3976604T3 (da) 1,3,4-oxadiazol-derivatforbindelser som histondeacetylase 6-hæmmer og den farmaceutiske sammensætning, der omfatter den samme
DK4299135T3 (da) Benzisoxazol-sulfonamid-derivater
DK3330259T3 (da) 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
DK3362445T3 (da) Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed
DK3494115T3 (da) N-(phenylsulfonyl)benzamidderivater som bcl-2-hæmmere
DK3292116T3 (da) 3-aryl-4-amido-bicykliske [4,5,0]hydroxamsyrer som hdac-inhibitorer
DK3612524T3 (da) 6-pyrimidin-isoindol-derivat som erk1/2-inhibitor
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
DK3297992T3 (da) Heterocykliske alkylderivatforbindelser som selektive histondeacetylase-inhibitorer og farmaceutiske sammensætninger omfattende samme
DK4110781T3 (da) 1,3,4-oxadiazolderivatforbindelser som histondeacetylase-6-hæmmer og farmaceutisk sammensætning, der omfatter disse
EP3976602A4 (en) 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF
DK3890828T3 (da) Heteroaromatiske forbindelser som vanin-hæmmere
DK3737470T3 (da) 3-phenyl-4-hexynsyrederivater som gpr40-agonister
DK4110780T3 (da) 1,3,4-oxadiazolderivatforbindelser som histondeacetylase-6-hæmmer og farmaceutisk sammensætning, der omfatter disse
IL318056A (en) 1,3,4-Oxadiazole Derivatives as Selective Histone Deacetylase 6 Inhibitors
EP3820859C0 (en) HISTONE DEACETYLASE INHIBITORS
EP4171538A4 (en) Selective histone deacetylase 6 inhibitors
DK3790873T3 (da) 1h-indazol-3-carboxamidforbindelser som glycogensynthase-kinase-3-beta-inhibitorer
DK3924361T3 (da) Nye triterpenderivater som hiv-hæmmere